

2019 Disclosure of Interest Information

GOLD BOARD OF DIRECTORS

Alvar G. Agusti, MD, Chair

Richard Beasley, MD

Bartolome R. Celli, MD

Rongchang Chen, MD

Gerard Criner, MD

David Halpin, MD

M. Victorina López Varela, MD

Maria Montes de Oca, MD

Kevin Mortimer, MD

Sundeep Salvi MD, PhD, FCCP, FRCP

Claus Vogelmeier, MD

GOLD SCIENCE COMMITTEE

Claus Vogelmeier, MD, Chair

Alvar G. Agusti, MD

Antonio Anzueto, MD

Peter J. Barnes MD

Jean Bourbeau, MD

Gerard Criner, MD

David Halpin, MD

MeiLan Han, MD MS

Fernando Martinez, MD

Maria Montes de Oca, MD

Alberto Papi, MD

Ian Pavord MA DM FRCP FERS FMedSci

Nicolas Roche, MD

Don D. Sin, MD

Dave Singh, MD

Rob Stockley, MD

M. Victorina López Varela, MD

Jadwiga A. Wedzicha, MD

January 1, 2019 - December 31, 2019

Background

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program is a collaboration between the scientific community and the private sector. The major objectives are: (1) to increase awareness of Chronic Obstructive Lung Disease among health professionals, health authorities, and the general public; (2) improve diagnosis, management, and prevention; and (3) stimulate research. These objectives are being met through preparation of scientific reports on Chronic Obstructive Lung Disease, dissemination and adoption of recommendations in these reports, and promotion of international collaboration on Chronic Obstructive Lung Disease research.

The purpose of this document is to safeguard the interests of all GOLD collaborators by an open disclosure of interests.

GOLD Structure

At present, the GOLD program is conducted through a GOLD Board of Directors that meets annually (usually in January), a Scientific Committee and a Dissemination Committee. Each Committee will have an active role in reviewing and recommending content for GOLD documents and all members will be asked to complete this form.

Annual Declaration of Interests

The following declarations are requested by GOLD. Please complete the company name select in the corresponding box whether you have financial relationships (received grants, personal fees, shares, non-financial support, other). Please include all companies in the bio-medical arena, as well as telehealth/technology, and tobacco entities. This form will be posted on the GOLD website after completion.

Definitions:

- 1. *Grants:* refers to any grant paid to your organization.
- 2. **Personal Fees:** refers to honorarium, consultation fees, etc for lectures, advisory committees or consultancy services either intermittent or regular, from which a GOLD member benefits personally. This includes ongoing attendance at advisory board meetings but would not normally include a situation where an individual is paid for a specific item or for attending or speaking at an occasional meeting.
- 3. **Shares:** refers to any shares in Chronic Obstructive Lung Disease-related commercial organizations, excluding unit trusts, pension plans or mutual funds, and it refers to shares held by a GOLD member or family members (spouse/children). The company is to be listed, not the number of shares.
- 4. *Non-Financial Support:* In-kind assistance.

The private sector should not in any way be involved in any aspect of developing documents, including collecting, reviewing or accessing the literature or determining the content. Once documents have been produced Chronic Obstructive Lung Disease-related commercial organizations can be involved in their dissemination and audit, including support for publications



Name: Alvar Agusti

Member of: BoD, ScC

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non- Financial Support?	Other?	Comments:
GSK	X	X			
AZ	X	X			
Menarini	X	X			
Chiesi	X	X			
Sanofi	X				
Nuvaira		X			
Zambon		X			

No SHARES

No Tobacco industry relationship



Name: Antonio Anzueto MD

Member of: Scientific Committee

Are there any relevant financial interests to disclose? (Yes)

		Personal	Non- Financial		
Name of Entity	Grant?	Fee?	Support?	Other?	Comments:
			•		Advisory Board,
GlaxoSmithKline		X			speaker
Theravance		X			Advisory Board, speaker
Boerhinger-Ingelheim		X			Advisory Board, speaker
Mylan		X			Advisory Board, speaker
Novartis		X			Advisory Board
Grifols		X			Advisory Board, speaker
Sunovion Pharmaceutical		X			Advisory Board, speaker
Verona Pharmaceutical		X			Advisory Board
Chiessi Pharma.		X			Advisory Board



Name: Peter Barnes

Member of: GOLD Scientific Committee 2019

Name of Entity	Grant?	Personal Fee?	Non- Financial Support?	Other?	Comments:
AstraZeneca	Yes	Yes	No	No	
GSK	No	Yes	No	No	
Boehringer Ingelheim	Yes	Yes	No	No	
Novartis	No	Yes	No	No	
Teva	No	Yes	No	No	
Pieris	No	Yes	No	No	
Heptaris	yes	No	No	No	
No shares					



Name: (ICHALD BEASLEY

Member of: GOLD BOARD OF TRUJECTS

المن المنافعة المنافعة المنافعة المنافعة ال	and the room to wondered	ر المان والمدرات الاستخداد والمدرات أن أن المراز والمدرات الاراد	alliteration	gar te dia mendia dia dia	المورد المور المورد المورد المور
Principal Marian	د در این در در کوره کاره این فرده	er i decizio i rigilia. L'Alexandria	g galanay (277) Garanay		وُ بيمار (فيرد) وديان والله الذ
Astra Zeneca	~	V			
Glars Smith Kline	~	\			
Genented	V				
Avillion		~			
Theravance		V			
Fisher & Payked Healthare	V				
				ļ	
				ļ	
				<u> </u>	
				<u> </u>	
				 	
				-	
					
				 	
		L		<u> </u>	



Name: Jean Bourbeau

Member of: Scientific Committee Global Initiative for COPD

			Non-		
Name of Entity	Grant?	Personal Fee?	Financial Support?	Other?	Comments:
CIHR	Yes				
Canadian Respiratory Research Network (CRRN)	Yes				
Canadian Thoracic Society		Yes			Consultant/Lecture
CHEST		Yes			Consultant/Lecture
Foundation of the MUHC	Yes				
Aerocrine	Yes				
AstraZeneca	Yes	Yes			Advisor/Lecture
Boehringer Ingelheim	Yes	Yes			Advisor/Lecture
Grifols	Yes	Yes			Advisor/Lecture
GlaxoSmithKline	Yes	Yes			Advisor/Lecture
Novartis	Yes	Yes			Advisor/Lecture
Trudell	Yes	Yes			Advisor/Lecture



Name: Bartolome Celli

Member of: GOLD Executive Committee

	1			1	
			Non-		
		Personal	Financial		
Name of Entity	Grant?	Fee?	Support?	Other?	Comments:
					Grant to
Astra Zeneca		Yes			institution
Boehringer Ingelheim		Yes			Consulting Fee
Novartis		Yes			Consulting Fee
Glaxo Smith Kline		Yes			Consulting Fee
Medimmune		Yes			Consulting Fee
Sanofi-Aventis		Yes			Consulting Fee
Chiesi		Yes			Consulting Fee
Menarini		Yes			Consulting Fee
Pulmonx		Yes			Consulting Fee



Name: Rongchang Chen

Member of: Director Borad

Are there any relevant financial interests to disclose? (Yes or No in each box)

Yes.

Name of Entity	Grant?	Personal Fee?	Non- Financial Support?	Other?	Comments:
GSK	√				
Astra-Zeneca	√	√			Speaker fee
Philips-Respironics	√	√			Speaker fee
Incentive Co	√				Speaker fee

Name: Gerard J. Criner, MD

Member of: GOLD BoD



Name of Entity	Grant?	Personal Fee?	Non- Financial Support?	Other?	Comments:
ALung Technologies, Inc.	Yes	No	No	No	
American College of Radiology	Yes	No	No	No	
American Lung Association	Yes	No	No	No	
Amgen	No	Yes	No	No	
AstraZeneca	Yes	Yes	No	No	
BioScale, Inc.	Yes	No	No	No	
Boehringer Ingelheim	Yes	Yes	No	No	
BREATH Therapeutics, Inc.	Yes	No	No	No	
Broncus Medical	No	Yes	No	No	
COPD Foundation	Yes	No	No	No	
Coridea/ZIDAN	Yes	No	No	No	
CSA Medical	No	Yes	No	No	
Dr. Karen Burns, St. Michael's Hospital	Yes	No	No	No	
Eolo Medical	No	Yes	No	No	
Fisher & Paykel Healthcare Limited	Yes	No	No	No	
Galapagos NV	Yes	No	No	No	
Gala Therapeutics	No	Yes	No	No	
GlaxoSmithKline	Yes	Yes	No	No	
Helios Medical	No	Yes	No	No	
HGE Health Care Solutions	No	No	No	Yes	Ownership Interest
Lungpacer Medical, Inc.	Yes	No	No	No	
Merck	No	Yes	No	No	
Medtronic	No	Yes	No	No	
Mereo BioPharma	No	Yes	No	No	
National Heart, Lung, & Blood Institute (NHLBI)	Yes	No	No	No	
NGM Biopharmaceuticals	No	Yes	No	No	
Nuvaira, Inc.	Yes	No	No	No	

Novartis	No	Yes	No	No	
Olympus	No	Yes	No	No	
PCORI	Yes	No	No	No	
Pulmonary Fibrosis Foundation	Yes	No	No	No	
PulmonX	Yes	Yes	No	No	
Respironics, Inc	Yes	Yes	No	No	
Respivant Sciences	Yes	Yes	No	No	
Spiration, Inc.	Yes	No	No	No	
Steward St. Elizabeth's Medical Center of Boston, Inc.	Yes	No	No	No	
The Implementation Group	No	Yes	No	No	
Verona Pharma	No	Yes	No	No	
Veracyte, Inc.	Yes	No	No	No	



Name: David Halpin

Member of: Board of Directors & Science Committee

		Personal	Non- Financial		
Name of Entity	Grant?	Fee?	Support?	Other?	Comments:
Boehringer Ingelheim		Υ	Υ		
Chiesi Pharmaceuticals		Υ			
GSK		Υ			
Novartis		Υ	Υ		
Pfizer		Υ			



Name: MeiLan Han

Member of: GOLD SC

Nama of Entity	Grant?	Personal Fee?	Non- Financial	Other?	Comments:
Name of Entity GSK	Grant		Support?	Other:	Comments:
BI		X			
AZ		X X			
Mylan					
Merck		X			
Sanofi				x	Investigator for a Sanofi sponsored clinical trial, funds paid to institution
Sunon				TA .	Drug supply to support NIH funded clinical
Novartis				X	trial
Sunovion				X	Research support for clinical trial

INTEREST

Name: Maria Victorina Lopez Varela

Member of: Board Directors



Name of Entity	Grant?	Personal Fee?	Non- Financial Support?	Other?	Comments:
Boehringer Ingelheim	No	Yes	No	No	Conference
AstraZeneca	No	Yes	No	No	Project Steering Committee



Name: Fernando Martinez

Member of: GOLD SC

		D1	Non- Financial		
Name of Entity	Grant?	Personal Fee?	Financial Support?	Other?	Comments:
·			•		COPD ad
	37 (1 '	37	X (1 1		boards, and study
AstraZeneca	X (academic productivity)	X (honoraria)	X (travel support)		steering committee
7 ISH azzeneca	productivity)	X	X (travel		ERS COPD
Boehringer Ingelheim		(honoraria)	support)		presentation
	X				COPD advisor –
D . E D.	(academic				supporting NIH
ProTerrixBio	productivity)				cohort study
Gala					COPD Ad board COPD ad
					boards, and study
	X				steering
	(academic	X	X (travel		committee and
GlaxoSmithKline	productivity)	(honoraria)	support)		DSMB
Teva		X (honoraria)	X (travel support)		COPD ad board
Teva		X	support)		COLD ad board
UpToDate		(honoraria)			COPD CME
	L			L	



Name: Maria Montes de Oca

Member of: Scientific Committee and Board of Directors

Name of Entity	Grant?	Personal Fee?	Non- Financial Support?	Other?	Comments:
Traine of Energy	Grant.	rec.	Support.	Other:	Speaker
AstraZeneca	No	Yes	No	No	committee fees
Boehringer Ingelheim	No	Yes	No	No	Speaker fees
Boeninger ingemenn	INO	1 68	INO	NO	Speaker rees

GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE DISCLOSURE OF INTEREST FOR THE PERIOD 01/01/2019 to 31/12/2019

Name: Kevin Mortimer

Member of GOLD BOD

Are there any relevant financial interests to disclose? Yes

Research grants:

- **Medical Research Council Doctoral Training Partnership**. Biagini G, <u>Mortimer K</u> (co-lead) and Diggle P. £1.3m. Translational and Quantitative Skills Doctoral Training Partnership in Global Health
- **Medical Research Council**. Mortimer K (PI). **£606,000**. Lung Health in Africa across the life course
- **National Institute for Health Research.** Squire SB, Mortimer K (co-l) et al. **£7m**. NIHR Global Health Research Unit on Lung Health and Tuberculosis in Africa at LSTM
- **Medical Research Council**. Biagini G, <u>Mortimer K</u> (co-lead) and Diggle P. £257,469. Liverpool School of Tropical Medicine and Lancaster University NPIF Studentships
- **Medical Research Council Skills Development Fellowship Programme**. Mortimer K (PI). **£580k**. Translational and Quantitative Skills Development Fellowships in Global Health
- **Medical Research Council NPIF Skills Development Fellowship.** Mortimer K (PI). **£286,000**. Translational and Quantitative NPIF Skills Development Fellowship in Global Health
- **Medical Research Council.** Allen S (PI), <u>Mortimer K</u> (co-I) et al. **£218,002**. Improving the survival, growth and developmental of low birth weight newborns through better nutrition
- **Medical Research Council**. Biagini G, <u>Mortimer K</u> (co-lead) and Diggle P. £188,132. Liverpool School of Tropical Medicine and Lancaster University NPIF Studentships
- **National Institute for Health Research.** Grigg J, Mortimer K (co-l) et al. **£2m**. NIHR Global Health Research Unit on improving asthma outcomes in African children at Barts and The London Queen Mary's School of Medicine and Dentistry
- **Wellcome Trust** Clinical PhD. Awarded to Sepedeh Saleh. <u>Mortimer K</u> (primary supervisor). **£455,000**. A new approach to air pollution in peri-urban Malawi.
- **The Academy of Medical Sciences**. Lesosky M (PI) and Mortimer K (co-I). £92.6k. Newton Advanced Fellowship: Biostatistical Methods for Bayesian Analysis of Multilevel Models of Lung Health in Africa.
- **Medical Research Council and Kenya National Research Fund Newton-Utafiti**. Mortimer K and Muhwa C (co-Pls). **£715k**. Non-communicable lung disease in Kenya: from burden and early life determinants to participatory inter-disciplinary solutions.
- **Medical Research Council Skills Development Fellowship Programme**. Mortimer K (PI). **£580k**. Translational and Quantitative Skills Development Fellowships in Global Health

		Personal	Non- Financial		
Name of Entity	Grant?	Fee?	Support?	Other?	Comments:
International Union against			•		KM is Director of
Tuberculosis and lung					Lung Health for
disease (The Union)		Χ			The Union
					Advisory board
AstraZeneca		Χ			fee

TOBACCO INDUSTRY FUNDING

x I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies

Signature

Date: 09/02/2020



Name: Alberto Papi

Member of: GOLD SC

Name of Entity	Grant?	Personal Fee?	Non- Financial Support?	Other?	Comments:
AstraZeneca	Yes	Yes	No	No	
Boehringer Ingelheim	Yes	Yes	No	No	
Chiesi Farmaceutici	Yes	Yes	No	No	
GlaxoSmithKline	Yes	Yes	No	No	
Mundipharma	No	Yes	No	No	
TEVA	Yes	Yes	No	No	
Novartis	Yes	Yes	No	No	
Zambon	No	Yes	No	No	
Sanofi	Yes	Yes	No	No	
Menarini	No	Yes	No	No	
Elpen Pharmaceutical	No	Yes	No	No	
MSD	No	Yes	No	No	
Avillion	No	Yes	No	No	

CHROME OF STRUCTURE AND STRUCT

Name: Ian Pavord

kan fann J

Member of: GOLD Science Committee

Are there any relevant financial interests to disclose?

In the last 5 years IDP has received speaker's honoraria for speaking at sponsored meetings from Astra Zeneca, Boehringer Inglehiem, Aerocrine, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron and GSK and payments for organising educational events from AZ, GSK, Sanofi/Regeneron and Teva. He has received honoraria for attending advisory panels with Genentech, Sanofi/Regeneron, Astra Zeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Circassia, Chiesi and Knopp and payments to support FDA approval meetings from GSK. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, Astra Zeneca, Teva and Chiesi. He has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. He is co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Merck, Bayer and Insmed. In 2014-5 he was an expert witness for a patent dispute involving Astra Zeneca and Teva.



Name: Nicholas Roche

Member of: GOLD Science Committee

		Personal	Non- Financial		
Name of Entity	Grant?	Fee?	Support?	Other?	Comments:
AstraZeneca		Yes			
Boehringer Ingelheim	Yes	Yes			
Chiesi		Yes			
Novartis	Yes	Yes			
Pfizer	Yes	Yes			
Sanofi		Yes			
Sandoz		Yes			
Mundipharma		Yes			
GSK		Yes			
3M		Yes			
AstraZeneca		Yes			



Name: Dr Sundeep Salvi

Member of: GOLD BoD

			Non-		
		Personal	Financial		
Name of Entity	Grant?	Fee?	Support?	Other?	Comments:
					Advisory Board
					of The Clean
Glaxo SmithKline (GSK),					Breathing
UK		Yes			Institute
Glenmark Pharmaceuticals,					
India		Yes			Giving Talk
		l	l .		



Name: Don D. Sin

Member of: GOLD Scientific Committee

		Personal	Non- Financial		
Name of Entity	Grant?	Fee?	Support?	Other?	Comments:
AstraZeneca	Yes	Yes			
Boehringer Ingelheim		Yes			
Nuvaira		Yes			



Name: Dave Singh

Member of: GOLD Science Committee

Nome of Endidor	Cuant?	Personal Eas?	Non- Financial	Oth or 2	Comments
Name of Entity AstraZeneca	Grant?	Fee?	Support?	Other?	Comments:
		Y			
Boehringer Ingelheim		Y		+	
Chiesi		Y			
Cipla		Y			
Genentech					
GlaxoSmithKline		Y			
Glenmark		Y			
Gossamerbio		Y			
Menarini		Y			
Mundipharma		Y			
Novartis		Y			
Peptinnovate		Y			
Pfizer		Y			
Pulmatrix		Y			
Theravance		Y			
Verona		Y			
				+	
_				-	



Name: R.Stockley

Member of: Scientific committee

			Non-		
Name of Entity	Grant?	Personal Fee?	Financial Support?	Other?	Comments:
Traine of Energy	Graner	1000	Support	Other	CI for phase 2
				Travel	study.
Mereo biopharma	Mac	VAC	no	fee to FDA	Therapeutic in vitro studies
Wereo diopharma	yes	yes	110	TDA	Steering board
CSL Behring	no	yes	no		and lecture fees
					DSMB for phase
Kamada	no	yes	no		3 study
Vertex	no	yes	no		Steering board
Z factor	no	Yes	no		Steering board
l				Travel	
Alpha one Foundation	yes	no	no	fee	
GSK	no	no	no	Lecture fee	
OSK	no	110	no	icc	



Name: Claus Vogelmeier

Member of: GOLD BoD

		n I	Non-		
Name of Entity	Grant?	Personal Fee?	Financial Support?	Other?	Comments:
Boehringer		Х			
CSL Behring		Х			
Chiesi		Χ			
GlaxoSmithKline		Χ			
Grifols		Χ			
Menarini		Х			
Novartis		Χ			
AstraZeneca	X	Х			
Nuvaira		х			



Name: Wisia Wedzicha

Member of: GOLD Science Committee

		Personal	Non- Financial		
Name of Entity	Grant?	Fee?	Support?	Other?	Comments:
GSK	Yes				
Astra Zeneca	Yes				
Chiesi	Yes				
Boehringer	Yes				
Novartis	Yes				